The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | In vivo CAR-T for multiple myeloma: promising findings from a small trial
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the exciting development of in vivo CAR T-cell therapy for multiple myeloma. Dr Schjesvold highlights the promising results of a small trial with three patients and notes that this approach has the potential to revolutionize the CAR-T field by simplifying the treatment process. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think definitely the most exciting thing on CAR-Ts at this Congress is something we will see on the late-breaking abstract session on Tuesday, is in vivo CAR. In vivo CAR is an off-the-shelf product. You don’t have to make it for a patient; it’s been made in the patient, so you inject the CAR T-cell product that finds the T-cells and creates the CAR-T within the patient. And of course, this is a very small trial so far – it’s three patients – but the three patients have shown the potential of this treatment; they are all MRD-negative after one month of treatment...
I think definitely the most exciting thing on CAR-Ts at this Congress is something we will see on the late-breaking abstract session on Tuesday, is in vivo CAR. In vivo CAR is an off-the-shelf product. You don’t have to make it for a patient; it’s been made in the patient, so you inject the CAR T-cell product that finds the T-cells and creates the CAR-T within the patient. And of course, this is a very small trial so far – it’s three patients – but the three patients have shown the potential of this treatment; they are all MRD-negative after one month of treatment. And that’s without lymphodepletion, the chemo you usually give before CAR-T. And it’s without the need to harvest the T-cells and bring them to some lab somewhere and get it back and so on; you just have a product, you inject it. So if this continues to show the potential we see here in three patients, this will change the CAR-T field completely, because then CAR-T becomes just a drug like other drugs, not the complicated logistics you need to have today.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
